What is Tazemetostat?

Tazemetostat is an orally taken investigational medicine that is the first of its kind targeting the EZH2 protein. The abnormal functioning of EZH2 in cells has been implicated in a number of different cancers. Tazemetostat has demonstrated anti-tumor activity by shrinking tumors and has been generally well tolerated when used as an investigational treatment in clinical trials for several types of cancer. Tazemetostat is currently being studied in multiple clinical trials for both blood cancers and solid tumor cancers.

Learn More about Tazemetostat

Clinical Trials in Cancer Research

Cancer clinical trials are research studies involving people living with cancer to determine if an investigational medicine is a safe and effective way of treating a particular type of cancer.

Genetically Defined Solid Tumors

Some types of cancers are driven by a mutation in certain genes that make proteins, which protect cells from turning cancerous. Cancers caused by changes in these genes are called genetically defined cancers. Examples of genetically defined cancers are those with changes in INI1 and SMARCA4 genes, which include rhabdoid tumors, renal medullary carcinoma, epithelioid sarcoma and synovial sarcoma, among others.

Epizyme is currently enrolling adults and children with genetically defined solid tumor cancers in clinical trials to evaluate tazemetostat as a potential treatment option for these cancers.

Learn More

Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (also known as NHL) is a form of blood cancer that starts in the body’s immune system. The most common types of NHL are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Epizyme is conducting a global clinical trial that is enrolling both adult patients with DLBCL and adult patients with FL to evaluate tazemetostat as a potential treatment option.

Learn More

Mesothelioma

Mesothelioma is a rare form of cancer that typically occurs in the lining of the lungs, but can also be found in the lining of other organs. Approximately 40-60% of patients diagnosed have a type of mesothelioma that is characterized by the absence or abnormal function of a protein known as BAP1*.

Epizyme is conducting a global clinical trial that is enrolling patients with mesothelioma, and in particular, patients with mesothelioma characterized by the absence or abnormal function of BAP1, to evaluate tazemetostat as a potential treatment option.

Learn More

 

*Reference 1 | *Reference 2